Cargando…

Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study

BACKGROUND: Type 2 diabetes (T2D) is expected to worsen the prognosis of inpatients with heart failure (HF) but the evidence from observational studies is inconsistent. We aimed to compare mortality outcomes and life expectancy among inpatients with HF with or without T2D and explored whether chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador, Dante, Bano, Arjola, Wehrli, Faina, Gonzalez-Jaramillo, Valentina, Laimer, Markus, Hunziker, Lukas, Muka, Taulant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339473/
https://www.ncbi.nlm.nih.gov/pubmed/37438747
http://dx.doi.org/10.1186/s12933-023-01903-7
_version_ 1785071851157848064
author Salvador, Dante
Bano, Arjola
Wehrli, Faina
Gonzalez-Jaramillo, Valentina
Laimer, Markus
Hunziker, Lukas
Muka, Taulant
author_facet Salvador, Dante
Bano, Arjola
Wehrli, Faina
Gonzalez-Jaramillo, Valentina
Laimer, Markus
Hunziker, Lukas
Muka, Taulant
author_sort Salvador, Dante
collection PubMed
description BACKGROUND: Type 2 diabetes (T2D) is expected to worsen the prognosis of inpatients with heart failure (HF) but the evidence from observational studies is inconsistent. We aimed to compare mortality outcomes and life expectancy among inpatients with HF with or without T2D and explored whether chronic kidney disease (CKD) influenced these associations. METHODS: We collected hospital and civil registry records of consecutive inpatients from a tertiary hospital in Switzerland with a diagnosis of HF from the year 2015 to 2019. We evaluated the association of T2D with mortality risk using Cox regression and adjusted for confounders. RESULTS: Our final cohort consisted of 10,532 patients with HF of whom 27% had T2D. The median age (interquartile range [IQR]) was 75 [68 to 82] and 78 [68 to 86] for the diabetes and non-diabetes groups, respectively. Over a median follow-up [IQR] of 4.5 years [3.3 to 5.6], 5,347 (51%) of patients died. T2D patients had higher risk of all-cause mortality (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.14 to 1.29). Compared to control (i.e. no T2D nor CKD), average life expectancy (95% CI) among T2D patients, CKD, or both was shorter by 5.4 months (95% CI 1.1 to 9.7), 9.0 months (95% CI 8.4 to 9.6), or 14.8 months (95% CI 12.4 to 17.2), respectively. No difference by sex or ejection fraction category was observed. CONCLUSIONS: T2D is associated with a significantly higher risk of all-cause mortality and shorter life expectancy compared to those without among middle-aged and elderly inpatients with HF; presence of CKD may further increase these risks. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01903-7.
format Online
Article
Text
id pubmed-10339473
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103394732023-07-14 Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study Salvador, Dante Bano, Arjola Wehrli, Faina Gonzalez-Jaramillo, Valentina Laimer, Markus Hunziker, Lukas Muka, Taulant Cardiovasc Diabetol Research BACKGROUND: Type 2 diabetes (T2D) is expected to worsen the prognosis of inpatients with heart failure (HF) but the evidence from observational studies is inconsistent. We aimed to compare mortality outcomes and life expectancy among inpatients with HF with or without T2D and explored whether chronic kidney disease (CKD) influenced these associations. METHODS: We collected hospital and civil registry records of consecutive inpatients from a tertiary hospital in Switzerland with a diagnosis of HF from the year 2015 to 2019. We evaluated the association of T2D with mortality risk using Cox regression and adjusted for confounders. RESULTS: Our final cohort consisted of 10,532 patients with HF of whom 27% had T2D. The median age (interquartile range [IQR]) was 75 [68 to 82] and 78 [68 to 86] for the diabetes and non-diabetes groups, respectively. Over a median follow-up [IQR] of 4.5 years [3.3 to 5.6], 5,347 (51%) of patients died. T2D patients had higher risk of all-cause mortality (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.14 to 1.29). Compared to control (i.e. no T2D nor CKD), average life expectancy (95% CI) among T2D patients, CKD, or both was shorter by 5.4 months (95% CI 1.1 to 9.7), 9.0 months (95% CI 8.4 to 9.6), or 14.8 months (95% CI 12.4 to 17.2), respectively. No difference by sex or ejection fraction category was observed. CONCLUSIONS: T2D is associated with a significantly higher risk of all-cause mortality and shorter life expectancy compared to those without among middle-aged and elderly inpatients with HF; presence of CKD may further increase these risks. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01903-7. BioMed Central 2023-07-12 /pmc/articles/PMC10339473/ /pubmed/37438747 http://dx.doi.org/10.1186/s12933-023-01903-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Salvador, Dante
Bano, Arjola
Wehrli, Faina
Gonzalez-Jaramillo, Valentina
Laimer, Markus
Hunziker, Lukas
Muka, Taulant
Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title_full Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title_fullStr Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title_full_unstemmed Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title_short Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
title_sort impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in switzerland: an ambispective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339473/
https://www.ncbi.nlm.nih.gov/pubmed/37438747
http://dx.doi.org/10.1186/s12933-023-01903-7
work_keys_str_mv AT salvadordante impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT banoarjola impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT wehrlifaina impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT gonzalezjaramillovalentina impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT laimermarkus impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT hunzikerlukas impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy
AT mukataulant impactoftype2diabetesonlifeexpectancyandroleofkidneydiseaseamonginpatientswithheartfailureinswitzerlandanambispectivecohortstudy